trending Market Intelligence /marketintelligence/en/news-insights/trending/0z9ww5fAX6ggSWt-kJM0hw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amgen's Nplate wins expanded US FDA approval for newly diagnosed patients

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Amgen's Nplate wins expanded US FDA approval for newly diagnosed patients

Amgen Inc. said the U.S. Food and Drug Administration expanded approval for its drug Nplate to treat newly diagnosed adults with a rare bleeding disorder called immune thrombocytopenia.

Nplate is now approved to treat newly diagnosed and persistent adult immune thrombocytopenia, or ITP, patients who have had an insufficient response to corticosteroids, immunoglobulins or surgery to remove the spleen.

ITP is an autoimmune disease that is characterized by low platelet counts in the blood and impaired platelet production. The disorder can lead to easy or excessive bruising and bleeding.

The estimated prevalence of the disease in the U.S. is 6.1 per 100,000 adults annually, and about 20,000 new patients are diagnosed each year, Amgen noted in its Oct. 18 press release.

Nplate, or romiplostim, was previously approved by the FDA to treat adults and children one year of age and older with ITP for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

The Thousand Oaks, Calif.-based biotech said the expanded approval is based on results from a mid-stage study, which showed that 93% of the patients achieved a higher platelet count during the 12-month period. Additionally, 32% of the patients maintained a higher platelet count for at least six months without taking any medication for immune thrombocytopenia.

The total sales for Nplate amounted to $201 million during the second quarter of 2019, an increase of 12% from the previous year period.